Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study
Abstract
Background The quadrivalent and bivalent human papillomavirus (HPV) vaccines are now licensed in several countries. We compared the cost-effectiveness of the HPV vaccines to provide evidence for policy decisions. Methods We developed HPV-ADVISE, a multi-type individual-based transmission-dynamic model of HPV infection and disease (anogenital warts, and cervical, anogenital and oropharyngeal cancers). We calibrated the model to sexual behavior and epidemiologic data from Canada, and estimated quality-adjusted life-years (QALYs) lost and costs ($CAN 2010) from the literature. Vaccine-type efficacy was based on a systematic literature review. The analysis was performed from the healthcare provider perspective, and costs and benefits were discounted at 3%. Predictions are presented using the median [10th;90th percentiles] of simulations. Results Under base-case assumptions (vaccinating 10-year-old girls, 80% coverage, $95/dose), using the quadrivalent and bivalent vaccines is estimated to cost $15,528 [12,056;19,140] and $20,182 [15,531;25,240] per QALY-gained, respectively. At equal price, the quadrivalent vaccine is more cost-effective than bivalent under all scenarios investigated, except when assuming longer duration of protection for the bivalent and minimal anogenital warts burden. Under base-case assumptions, the maximum additional cost per dose for the quadrivalent vaccine to remain more cost-effective than the bivalent is $32 [17;46] (using a $40,000/QALY-gained threshol…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The study used a comparative modelling approach including three models that have been extensively peer reviewed and validated with post-vaccination surveillance data.
“First, we used a comparative modelling approach including three models that have been extensively peer reviewed and validated with post-vaccination surveillance data.30, 31, 32, 33, 34, 35, 36”
Cites
Gold, M. R., Franks, P., McCoy, K. I., & Fryback, D. G. (1998) · Medical Care · doi:10.1097/00005650-199806000-00002 · Cited by 357 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M.-C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30068-4 · Cited by 943 · see citing works
Self-citation
- Authors
- Brisson, M., Laprise, J.-F., Drolet, M., Van de Velde, N., Franco, E. L., Kliewer, E. V., Ogilvie, G., Deeks, S. L., & Boily, M.-C.
- Affiliations
- Centre de recherche du CHU de Québec-Université Laval (CA)
- Université Laval (CA)
- McGill University (CA)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Public Health Ontario (CA)
- Imperial College London (GB)
- Corresponding author
- Brisson, Marc
- ORCID
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 31
- Issue
- 37
- Pages
- 3863-3871
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2040954271
- Cited by
- 56
- References
- 1
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 1 · 2020: 7 · 2019: 3 · 2018: 6 · 2017: 9 · 2016: 7 · 2015: 8 · 2014: 6 · 2013: 3
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (CRN-83320)
- Québec Ministry of Health
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Surgery › Genital Health and Disease
- Keywords
- HPV vaccine, quadrivalent HPV vaccine, bivalent HPV vaccine, cost-effectiveness, HPV transmission dynamics, genital warts, cervical cancer, oropharyngeal cancer, anogenital cancer, preadolescent girls, vaccine price, vaccine protection duration, quality-adjusted life years
- MeSH terms
- Canada, Uterine Cervical Neoplasms, Child, Condylomata Acuminata, Cost-Benefit Analysis, Costs and Cost Analysis, Female, Humans, Male, Models, Theoretical, Oropharyngeal Neoplasms, Sexual Behavior, Vaccination, Models, Economic, Quality-Adjusted Life Years, Papillomavirus Infections, Papillomavirus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
